Purpose:To assess safety and search predictive factors of efficacy of a single intra-articular injection of a mannitol-modified hyaluronic acid (HA) viscosupplement, in patients having trapeziometacarpal (TMC) osteoarthritis (OA).Methods:Patients with symptomatic TMC OA, not adequately relieved by analgesic therapy and/or by the use of a thumb splint, were included in a 3-month prospective multicentre open-label trial. All underwent plain radiographs with the Kapandji incidences allowing the Dell radiological grade assessment (1-4). Primary end point was the variation between injection (D0) and day 90 (D90) of the thumb pain (11-point Likert scale). Treatment consisted in a single injection of 0.6 to 1 mL of a viscosupplement made of a cross-linked HA combined with mannitol. All injections were performed under imaging guidance. Predictive factors of pain decrease were studied in univariate and multivariate analysis.Results:A total of 122 patients (76% women, mean age 60, mean disease duration 36 months) were included and 120 (98%) were assessed at 3 months. The TMC OA was of Dell’s grade 1, 2, 3, and 4 in 23%, 36.8%, 36.8%, and 3.5% of cases, respectively. At D0, the average (SD) pain level was 6.5 ± 1.6 without significant difference between Dell groups (P = .21). At day 90, pain decreased from 6.5 ± 1.6 to 3.9 ± 2.5 (difference −2.7 ± 2.5; −42%; P < .0001) without significant difference between Dell grade (P = .055), despite a seemingly smaller number of responders in stage 2 patients. The average analgesic consumption decreased in more than 1 out of 2 patients. In multivariate analysis, no predictor of response was identified. There was no safety issue. All adverse events (11%) were transient increase in pain during or following HA administration and resolved without sequel within 1 to 7 days.Conclusions:This study suggests that a single course of HANOX-M-XL injection is effective in relieving pain in patients with TMC OA, without safety concern. Patients with advanced stage of OA benefit the treatment as much as those with mild or moderate OA.
BackgroundViscosupplementation is likely effective to alleviate pain and improve function in patients suffering from rhizarthrosis. However no study has been focused on the predictors of efficacy of the treatment.ObjectivesTo search predictive factors of success or failure 3 months after a single intra-articular injection of a mannitol-modified hyaluronic acid (HA) viscosupplement, in patients suffering from trapeziometacarpal (TMC) osteoarthritis (OA).MethodsPatients with symptomatic TMC OA were included in a 3 month prospective multicentre open-label trial. To be included in the study patients must have symptomatic TMC OA, not adequately relieved by analgesics/NSAIDs therapy and/or by the use of a thumb splint. Before treatment all patients must have had plain radiographs with the Kapandji incidences, for the Dell radiological grade assessment. (1 to 4). Primary endpoints were the variation between injection (D0) and day 90 (D90) of the thumb pain measured on 11 point-Likert scale (0 to 10) and the patient‘s self-assessment of efficacy (0 to 3). Treatment consisted in a single injection of 0.6 to 1 ml of HANOX-M-XL, a viscosupplement made of a cross-linked HA of high molecular weight, from biofermentative origin, combined with mannitol. All injections were performed under fluoroscopic or ultrasound guidance. Predictive factors of pain decrease were studied in univariate and multivariate analysis. All statistical tests were carried out two tailed at the 5% level of significance.Results122 patients (76% females, mean age 60, mean disease duration 36 months) were included and 120 (98%) were assessed at 3 months. 23% of the TMC OA were grade 1 according to Dell classification, 36.8% grade 2, 36.8% grade 3% and 3.5% grade 4. At D0, the average (SD) pain level was 6.5±1.6 without significant difference between Dell groups (p=0.21). At day 90, pain decreased from 6.5±1.6 to 3.9±2.5 (Difference −2.7±2.5; −42%; p<0.0001) without significant difference depending on the Dell grade (p=0.055), despite a seemingly smaller number of responders in stage 2 patients. The average analgesic consumption decreased in more than one out of two patients. In univariate analysis, the clinical response was significantly worse in patients taking NSAIDs at baseline (p=0.012), but this difference no longer reached the significance threshold in the multivariate analysis. In multivariate analysis no predictor of response was identified. There was no safety issue. All AEs (11%) were transient increase of pain during or following HA administration and resolved without sequel within 1 to 7 days.ConclusionsThis study, of the largest cohort of patients treated with viscosupplementation in TMC OA, suggests that a single course of HANOX-M-XL injection is effective in relieving pain, without safety concern. Interestingly patients with the more advanced stages of OA seemed to benefit the treatment as well as those with less advanced OA.Disclosure of InterestJ. DAUVISSAT: None declared, T. Conrozier Consultant for: Labrha SAS, Speakers bureau: Labrha SAS...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.